[1] BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults. Retrieved April 6, 2022, from https://www.globenewswire.com/news-release/2022/04/06/2417422/0/en/BioXcel-Therapeutics-Announces-FDA-Approval-of-IGALMI-dexmedetomidine-Sublingual-Film-for-Acute-Treatment-of-Agitation-Associated-with-Schizophrenia-or-Bipolar-I-or-II-Disorder-in-.html
[2] A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia. Retrieved April 6, 2022, from https://www.biospace.com/article/a-win-for-ai-fda-approves-bioxcel-s-treatment-for-bipolar-and-schizophrenia/